vs

Side-by-side financial comparison of BK Technologies Corp (BKTI) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

BK Technologies Corp is the larger business by last-quarter revenue ($21.5M vs $12.5M, roughly 1.7× Avidity Biosciences, Inc.). BK Technologies Corp runs the higher net margin — 19.7% vs -1398.3%, a 1418.0% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 20.0%). BK Technologies Corp produced more free cash flow last quarter ($2.8M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs -21.6%).

BK Technologies Corp designs, manufactures and sells analog and digital two-way radio communications equipment and related accessories. It serves public safety departments, first responders, government agencies and commercial clients primarily across North America, focusing on reliable, mission-critical communication solutions.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

BKTI vs RNA — Head-to-Head

Bigger by revenue
BKTI
BKTI
1.7× larger
BKTI
$21.5M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+414.1% gap
RNA
434.0%
20.0%
BKTI
Higher net margin
BKTI
BKTI
1418.0% more per $
BKTI
19.7%
-1398.3%
RNA
More free cash flow
BKTI
BKTI
$159.7M more FCF
BKTI
$2.8M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
-21.6%
BKTI

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
BKTI
BKTI
RNA
RNA
Revenue
$21.5M
$12.5M
Net Profit
$4.2M
$-174.4M
Gross Margin
50.5%
Operating Margin
19.7%
-1513.5%
Net Margin
19.7%
-1398.3%
Revenue YoY
20.0%
434.0%
Net Profit YoY
15.6%
-117.0%
EPS (diluted)
$1.06
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BKTI
BKTI
RNA
RNA
Q4 25
$21.5M
Q3 25
$24.4M
$12.5M
Q2 25
$21.2M
$3.8M
Q1 25
$19.1M
$1.6M
Q4 24
$17.9M
$3.0M
Q3 24
$20.2M
$2.3M
Q2 24
$20.3M
$2.0M
Q1 24
$3.5M
Net Profit
BKTI
BKTI
RNA
RNA
Q4 25
$4.2M
Q3 25
$3.4M
$-174.4M
Q2 25
$3.7M
$-157.3M
Q1 25
$2.1M
$-115.8M
Q4 24
$3.7M
$-102.3M
Q3 24
$2.4M
$-80.4M
Q2 24
$1.7M
$-70.8M
Q1 24
$-68.9M
Gross Margin
BKTI
BKTI
RNA
RNA
Q4 25
50.5%
Q3 25
49.9%
Q2 25
47.4%
Q1 25
47.0%
Q4 24
41.2%
Q3 24
38.8%
Q2 24
37.3%
Q1 24
Operating Margin
BKTI
BKTI
RNA
RNA
Q4 25
19.7%
Q3 25
19.8%
-1513.5%
Q2 25
18.9%
-4448.7%
Q1 25
15.3%
-8360.9%
Q4 24
12.3%
-4069.6%
Q3 24
12.9%
-4200.9%
Q2 24
10.0%
-4040.4%
Q1 24
-2178.6%
Net Margin
BKTI
BKTI
RNA
RNA
Q4 25
19.7%
Q3 25
14.1%
-1398.3%
Q2 25
17.7%
-4089.3%
Q1 25
11.2%
-7360.0%
Q4 24
20.4%
-3439.5%
Q3 24
11.7%
-3441.7%
Q2 24
8.2%
-3461.8%
Q1 24
-1943.4%
EPS (diluted)
BKTI
BKTI
RNA
RNA
Q4 25
$1.06
Q3 25
$0.87
$-1.27
Q2 25
$0.96
$-1.21
Q1 25
$0.55
$-0.90
Q4 24
$0.96
$-0.80
Q3 24
$0.63
$-0.65
Q2 24
$0.47
$-0.65
Q1 24
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BKTI
BKTI
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$22.8M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$44.7M
$1.9B
Total Assets
$63.8M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BKTI
BKTI
RNA
RNA
Q4 25
$22.8M
Q3 25
$21.5M
$350.2M
Q2 25
$11.9M
$243.9M
Q1 25
$8.9M
$254.2M
Q4 24
$7.1M
$219.9M
Q3 24
$4.2M
$370.2M
Q2 24
$3.0M
$575.8M
Q1 24
$471.4M
Stockholders' Equity
BKTI
BKTI
RNA
RNA
Q4 25
$44.7M
Q3 25
$41.0M
$1.9B
Q2 25
$36.8M
$1.2B
Q1 25
$32.4M
$1.3B
Q4 24
$29.8M
$1.4B
Q3 24
$26.0M
$1.5B
Q2 24
$23.4M
$1.2B
Q1 24
$830.9M
Total Assets
BKTI
BKTI
RNA
RNA
Q4 25
$63.8M
Q3 25
$66.9M
$2.1B
Q2 25
$60.4M
$1.4B
Q1 25
$56.1M
$1.5B
Q4 24
$51.5M
$1.6B
Q3 24
$46.4M
$1.6B
Q2 24
$48.9M
$1.3B
Q1 24
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BKTI
BKTI
RNA
RNA
Operating Cash FlowLast quarter
$3.0M
$-156.2M
Free Cash FlowOCF − Capex
$2.8M
$-156.9M
FCF MarginFCF / Revenue
13.2%
-1257.6%
Capex IntensityCapex / Revenue
0.7%
5.7%
Cash ConversionOCF / Net Profit
0.71×
TTM Free Cash FlowTrailing 4 quarters
$18.4M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BKTI
BKTI
RNA
RNA
Q4 25
$3.0M
Q3 25
$10.4M
$-156.2M
Q2 25
$3.9M
$-199.7M
Q1 25
$2.1M
$-124.8M
Q4 24
$3.8M
$-99.9M
Q3 24
$5.7M
$-65.6M
Q2 24
$4.1M
$-65.0M
Q1 24
$-70.4M
Free Cash Flow
BKTI
BKTI
RNA
RNA
Q4 25
$2.8M
Q3 25
$10.1M
$-156.9M
Q2 25
$3.7M
$-203.0M
Q1 25
$1.8M
$-128.6M
Q4 24
$3.4M
$-103.8M
Q3 24
$5.2M
$-67.3M
Q2 24
$3.9M
$-65.5M
Q1 24
$-71.3M
FCF Margin
BKTI
BKTI
RNA
RNA
Q4 25
13.2%
Q3 25
41.3%
-1257.6%
Q2 25
17.3%
-5277.1%
Q1 25
9.6%
-8174.3%
Q4 24
19.2%
-3491.0%
Q3 24
25.8%
-2881.8%
Q2 24
19.2%
-3204.6%
Q1 24
-2012.3%
Capex Intensity
BKTI
BKTI
RNA
RNA
Q4 25
0.7%
Q3 25
1.5%
5.7%
Q2 25
1.2%
86.9%
Q1 25
1.4%
238.6%
Q4 24
2.0%
131.7%
Q3 24
2.2%
72.9%
Q2 24
1.0%
26.0%
Q1 24
25.8%
Cash Conversion
BKTI
BKTI
RNA
RNA
Q4 25
0.71×
Q3 25
3.04×
Q2 25
1.04×
Q1 25
0.98×
Q4 24
1.04×
Q3 24
2.40×
Q2 24
2.46×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons